Mineralys Therapeutics, Inc. filings document the public-company disclosures of a biopharmaceutical issuer developing lorundrostat for hypertension and related comorbidities driven by dysregulated aldosterone. Form 8-K reports cover quarterly and annual financial results, corporate updates, Regulation FD disclosures, FDA acceptance of the lorundrostat New Drug Application, and clinical results from the Explore-OSA exploratory trial.
The filing record also includes proxy materials for annual meeting voting and stockholder procedures, along with material-event disclosures for capital-structure matters. These include common stock arrangements under an ATM Equity Offering Sales Agreement, registration-statement references, material agreements, and shareholder voting matters.
Mineralys Therapeutics, Inc. officer Rodman David Malcom reported a proposed sale of 3,542 common shares, with October 13, 2026 listed as the approximate sale date. The notice gives an aggregate market value of $78,065.68 and attributes the shares to an exercise of employee stock options, noting a broker-assisted cashless exercise and naming Merrill Lynch as broker. It also lists earlier common-stock sales by David Rodman from July 9 through September 17, 2026.
Mineralys Therapeutics, Inc. (MLYS) Chief Executive Officer Jon Congleton sold 75,000 shares of common stock on September 30, 2026, at a weighted-average price of $25.4622 per share. The shares were sold in multiple transactions at prices ranging from $25.0000 to $25.8201 under a Rule 10b5-1 trading plan adopted on December 23, 2025. After the sale, Congleton directly held 528,621 shares.
Mineralys Therapeutics, Inc. (MLYS) is the issuer named in Jon Congleton’s notice of a proposed sale of 75,000 common shares, with an aggregate market value of $1,909,661.61. Congleton is identified as an officer and director; the securities information lists 88,406,885 shares outstanding as of September 30, 2026. The notice also lists prior sales by Congleton: 75,000 shares for $1,960,601.58 on June 30, 2026, and 10,700 shares for $291,441.17 on July 13, 2026.
Mineralys Therapeutics, Inc. (MLYS) director Brian Taylor Slingsby reported that Catalys Pacific Fund, LP sold 104,320 common shares on September 22, 2026, at a weighted-average price of $28.8085 per share. The sales occurred in multiple transactions at prices from $28.700 to $28.905, and the fund held 7,805,718 shares following the sale. Slingsby may be deemed to share voting and investment power over the fund’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest. No Rule 10b5-1 plan is reported.
Mineralys Therapeutics, Inc. (MLYS) reported that Chief Commercial Officer Warren Eric exercised stock options for 7,438 shares of common stock on September 21, 2026 at an exercise price of $13.24 per share and sold the same 7,438 shares at a weighted-average price of $28.1172 per share. These transactions were effected pursuant to a Rule 10b5-1 stock selling plan adopted on March 27, 2026. Following the option exercise, Eric held 230,563 stock options directly, expiring on April 21, 2035, subject to the stated vesting schedule.
Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock for which Catalys Pacific Fund has filed a notice to sell shares under Rule 144. The notice covers 104,320 shares of common stock, with an indicated aggregate market value of $3,005,302.72 and notes 88,406,885 shares outstanding as of September 22, 2026.
The shares to be sold were acquired on June 1, 2022 in a private acquisition from the issuer or an affiliate for cash. Morgan Stanley Smith Barney LLC Executive Financial Services is listed as the broker for potential sales on NASDAQ.
Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock that an officer, Eric Warren, has filed a notice to sell under Rule 144. The notice covers a proposed sale of 7,438 shares of common stock on September 21, 2026 through a broker assisted cashless exercise of employee stock options. The filing also lists several prior sales of Mineralys common stock by Warren during the preceding three months.
Mineralys Therapeutics, Inc. (MLYS) director Daphne Karydas reported an option exercise and share sale on September 15, 2026. She exercised stock options for 3,000 shares of common stock at an exercise price of $12.02 per share, leaving 35,000 options outstanding under that award. On the same date, she sold 3,000 common shares at $28.58 per share. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 22, 2025, and the option is scheduled to vest in 36 monthly installments beginning October 13, 2023, with an expiration date of September 13, 2033.
Mineralys Therapeutics, Inc. (MLYS) received a Rule 144 notice from officer David Rodman covering the planned sale of 417 shares of common stock on September 17, 2026, through Merrill Lynch in a broker-assisted cashless exercise of employee stock options.
The notice also lists prior Rule 144 sales of Mineralys common stock by David Rodman over the past three months, including several block transactions between June 12, 2026 and September 14, 2026 with individual trades such as 14,058 shares for $387,716.51 on July 13, 2026.
Mineralys Therapeutics, Inc. (MLYS) is the issuer of common stock that officer Daphne Karydas plans to sell under Rule 144. The notice covers a planned sale of 3,000 shares of common stock on September 15, 2026, through a broker-assisted cashless exercise of employee stock options handled by Merrill Lynch.
These planned sales are in addition to a prior sale of 3,000 shares of common stock on June 17, 2026, for proceeds of $75,000 during the preceding three months.